BLA 021211 · Organon USA LLC
Follistim Aq
Follitropin Alfa/Beta · Subcutaneous · Gonadotropin
Last checked: Nov 20, 2026Latest source record: Feb 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Mar 23, 2004
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
62
13 Phase 3, 3 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Follitropin Alfa/Beta" as an intervention, any sponsor and status, largest first.
- A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00696800 · 1,509 participants · Start Jun 27, 2006 · Primary completion Nov 19, 2007
Drug: Corifollitropin alfa; RecFSH / Follitropin beta (Days 1 to 7) and 6 more · For: In Vitro Fertilization
- Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01144416 · 1,424 participants · Start Jun 2010 · Primary completion Jul 2011
Drug: SCH 900962 / Corifollitropin alfa / Org 36286; RecFSH / follitropin beta and 2 more · For: Infertility
Lund UniversityAcademic, hospital or other
NCT03737253 · 810 participants · Start Sep 2016 · Primary completion Dec 31, 2021
Drug: Follitropin alpha; Menotropin · For: Female Infertility
Sites: Poznan, Poland; Malmö, Sweden
- MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo TransferPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00884221 · 749 participants · Start Jul 2009 · Primary completion Jul 2010
Drug: Highly purified menotrophin; Recombinant FSH · For: Infertility
Sites: Anderlecht, Belgium; Brussels, Belgium; Edegem, Belgium · 25 sites in all
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist TreatmentPivotal-lookingRecruiting
Nanjing UniversityAcademic, hospital or other
NCT07128394 · 590 participants (planned) · Start Feb 1, 2024 · Primary completion Sep 30, 2026
Drug: Recombinant Luteinizing Hormone (rLH); Recombinant Follicle-Stimulating Hormone (rFSH) and 1 more · For: Infertility, Female; Luteinizing Hormone (LH)
Sites: Nanjing, China
- Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response PatientPivotal-lookingCompleted
Reproductive & Genetic Hospital of CITIC-XiangyaAcademic, hospital or other
NCT03300518 · 552 participants · Start Nov 15, 2017 · Primary completion Jun 18, 2021
Drug: Follitropin Beta;MSD; Ganirelix and 2 more · For: Infertility
Sites: Changsha, China
- Nordic Luveris StudyPivotal-lookingCompleted
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT00553293 · 526 participants · Start Aug 2003
Drug: recombinant luteinizing hormone (Luveris); recombinant follicle stimulating hormone (Gonal-f) · For: Infertility; In Vitro Fertilization
Sites: Copenhagen, Denmark
- Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) PatientsPivotal-lookingCompleted
Vietnam National UniversityAcademic, hospital or other
NCT02466204 · 400 participants · Start Jun 1, 2015 · Primary completion Aug 10, 2016
Drug: corifollitropin alfa; Follitropin Beta · For: Infertility
Sites: Ho Chi Minh City, Vietnam · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis.
Palomba S, Caserta D, Levi-Setti PE, et al. · J Ovarian Res 2024 · Meta-Analysis, Systematic Review
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.